Skip to main content
OpenTrials
Completed

NCT Number: NCT03053713

The Effect of Diet on Disease Activity and Symptoms in Patients With Ulcerative Colitis

The Mediterranean Diet Pattern (MDP) has been shown to have beneficial effects on the intestinal bacteria and the immune system in diseases like cancer and diabetes. The aim of this study is to determine if a MDP will have an impact on symptoms, intestinal bacteria and the immune system in Ulcerative Colitis (UC). Symptoms, blood and stool will be examined to determine if the MDP results in changes to the intestinal bacteria or immune system.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of British Columbia - Okanagan

Kelowna, British Columbia, V1V 1V7, Canada

About this study

Few studies have found a single dietary factor as being protective or detrimental against inflammatory bowel disease (IBD), therefore novel diet approaches for the prevention and treatment of IBD are urgently needed. The Mediterranean Diet Pattern (MDP) is associated with improvements in health status and inflammatory markers in healthy individuals and rodent models of colitis. Reductions in inflammatory biomarkers and a "normalization" of the gut microbiota have been shown in patients with Crohn's disease following a MDP. To date, no studies have examined the effect of MDP on disease activity, inflammatory markers or the effects on the microbiome in ulcerative colitis (UC).

This study will examine the effects of a MDP taken by patients with UC on 1) symptoms, clinical and quality of life endpoints and 2) on gut microbiome and fecal immune biomarkers. One hundred subjects and two subjects with UC will be randomly allocated to follow a MDP for 12 weeks or their usual diet (controls). Upon initiation, throughout and completion of each diet, symptoms, clinical and quality of life endpoints will be monitored. Fecal samples will be collected to assess pH, short-chain fatty acid concentrations, bacterial abundance and diversity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ulcerative Colitis in clinical remission (partial Mayo score 0-1)
  • Taking oral 5-ASA, methotrexate, azathioprine or 6-mecaptopurine as long as there have been no changes in dosage for 2 months prior to the start of the study
  • Generally healthy besides having UC
  • Agree not to use any dietary supplements, herbal treatments, prebiotics, probiotics or diet therapies within three weeks of the onset of the trial or during the study

Exclusion criteria

  • Using prednisone (or steroid equivalent) or biologics (i.e., infliximab, adalimumab, vedolizumab) at the time of enrollment
  • Using antibiotics two weeks prior to or anytime during the study period
  • Pregnancy, lactation or desire to become pregnant during the study period because we do not know if or how an unborn baby/fetus could be harmed
  • History of colectomy or extensive colonic resection or disease is limited to the rectum
  • Significant chronic disorders such as severe cardiac disease, significant renal failure, severe pulmonary disease (need for oxygen)
  • Active gastrointestinal infection (e.g., C. difficile infection)
  • Severe psychiatric disorder
  • Unable or unwilling to consent
  • Unable to comply with study requirements
  • Presence of alcohol or drug abuse

Treatment and study plan

Mediterranean diet pattern

Behavioral

Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.

Habitual diet (control)

Behavioral

Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.

Primary outcomes

  1. Simple Clinical Colitis Activity Index (SCCAI)

    Time frame: Change from baseline to week 12

    The SCCAI is a symptom-based disease activity index that uses six clinical parameters: daytime and nocturnal bowel frequency, urgency, amount of blood in the stool, well-being and extraintestinal manifestations. A reduction of SCCAI >1.5 is considered clinically significant and SCCAI score of <4 is indicative of remission.

Secondary outcomes

  1. Short Inflammatory Bowel Disease Questionnaire (SIBDQ)

    Time frame: 12 weeks

    Quality of life improvement measured at baseline, week 3, week 6, week 9 and 12.

  2. Fecal microbiota

    Time frame: 12 weeks

    Fecal microbiota measured by examining microbial taxa from stool at baseline and 12 weeks

  3. Change in mucosal inflammation measured by fecal calprotectin

    Time frame: 12 weeks

    Change in mucosal inflammation will be measured by fecal calprotectin at baseline and week 12

  4. Change in serum marker of inflammation (serum CRP)

    Time frame: 12 weeks

    Change in markers of inflammation will be measured by serum CRP

  5. Change in serum marker of inflammation (serum ferritin)

    Time frame: 12 weeks

    Change in markers of inflammation will be measured by serum ferritin

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Collaborators

  • Canadian Foundation for Dietetic Research (CFDR)

Registry information

Official study title

The Effect of Diet Modification on Clinical Disease Activity, the Gut Microbiome and Immune Responses in Patients With Ulcerative Colitis

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Feb 15, 2017
Registry last updated
May 23, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.